Nexag (Tranexamic Acid)

Tranexamic Acid, the active ingredient in Nexag, is an antifibrinolytic presented as an oral dosage form for oral use. It reduces excessive bleeding by stabilizing blood clots and is indicated for heavy menstrual bleeding, trauma‑related bleeding, and surgical bleeding control.

GNH USA supplies Nexag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The product meets EU pharmacopeial standards and is manufactured under strict Good Manufacturing Practice guidelines.

Tranexamic Acid is used to reduce bleeding in conditions where fibrinolysis is excessive.

- Heavy menstrual bleeding (menorrhagia): reduces menstrual blood loss and improves quality of life. - Trauma‑related bleeding: helps control hemorrhage in traumatic injuries and emergency settings. - Surgical bleeding control: minimizes intra‑operative blood loss during various surgeries. - Dental procedures in patients with bleeding disorders: stabilizes clot formation to prevent excessive oral bleeding.

Tranexamic Acid may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Renal impairment: worsening kidney function in susceptible patients.

Tranexamic Acid should be used with careful clinical assessment and monitoring.

- Assess bleeding risk: evaluate patient history before initiating therapy. - Monitor renal function: adjust use in patients with kidney impairment. - Avoid in active thromboembolic disease: contraindicated if patient has recent clot. - Use with caution in pregnancy: limited data, weigh benefits vs risks. - Review concomitant medications: consider interactions with anticoagulants and hormonal therapies. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Tranexamic Acid can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with pro‑coagulant agents (e.g., factor VIIa): may increase clot risk. - Combined with hormonal contraceptives: heightened thrombotic potential.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): may reduce anticoagulant effect. - Antiplatelet drugs (aspirin, clopidogrel): monitor for altered bleeding. - NSAIDs: increased gastrointestinal irritation.